Clinically Proven Plaque Analysis Now Covered for 90% of Arizona Patients1

Preventive Action for a Progressive Threat.

Heartflow Plaque Analysis delivers a comprehensive, AI-driven assessment of coronary artery disease. By quantifying total plaque volume and composition, including high-risk non-calcified plaque, it enables you to deliver more personalized preventive care for every patient.
frame 1322
admin ajax

The Largest Prospective Registry on Plaque Analysis in Coronary Artery Disease1

The DECIDE Registry is a landmark prospective study of 22,000 patients at over 30 centers across the United States.

Over 50% of Patients

had their medical management changed when Plaque Analysis with Plaque Staging* was added compared to their management based on CCTA alone.

~1/3 of Patients

with a CAC score of 0 had a change in management compared to CCTA alone.

~15% Expected Decrease in Risk of Cardiac Event

for patients with a change in management.

Majority of Lives in Arizona Now Have Access to Plaque Analysis

Plaque Analysis is covered by major insurers in the state:

  • • Medicare
  • • UnitedHealthcare
  • • Blue Cross Blue Shield of Arizona
  • • Cigna

Medical Necessity Guidelines

Plaque Analysis is considered reasonable and medically necessary as a diagnostic study when:

  1. The patient is eligible for CCTA, and;
  2. The patient presents with acute or stable chest pain and is at intermediate risk for CAD or has evidence of CAD-RADS level 1, 2, or 3 disease (>0 and <70 stenosis) on their CCTA and;
  3. The patient is negative or inconclusive for acute coronary syndrome (ACS)
map 1

Transform Plaque Insights into Decisive Action

With coverage in place for your patients, it’s time to leverage Plaque Analysis to deliver more personalized preventive care. Connect with your Heartflow representative to find out how to order this test.
Hear From Your Peers
dr shaw

“Slightly more than half of patients had a very positive change in management intensification of preventive care, which is really what we want to have happen out of that interaction.”

Leslee Shaw, PhD,
Director, Blavatnik Family Research Institute,
Icahn School of Medicine at Mount Sinai New York, NY

Plaque Staging*: How Insights Transform Into Action

Demonstrated by the DECIDE Registry, Plaque Staging* is the most clinically validated tool for informing actionable treatment plans based on total plaque volume, simplifying decision-making and personalizing preventive treatment based on patient risk.1,3
Learn More
plaque staging